Martin Murphy

Jim Phillips, CEO

Jim has over 20 years healthcare industry experience, and is a qualified physician with an MBA from Cass Business School. Jim worked for Johnson & Johnson and Novartis in senior executive roles, and was founder & chief executive officer of Talisker Pharmaceuticals Ltd, which was acquired by EUSA Pharma Inc in July 2006 giving investors a successful exit. Jim also took Bone Medical Ltd through its oversubscribed IPO in Australia in 2004 (as Chief Executive).

Jim is currently non-executive chairman of Prosonix Ltd, and has held a number of other international board level roles including organizations such as West Sussex Health Authority, Lifegard Technologies Ltd, CRF Inc, Diabetology Ltd, EUSA Pharma Inc, OPi S.A. Jim has extensive experience in clinical, business development, and commercialisation in pharmaceuticals, and also in leading the development of early stage ventures.

Graham Boulnois

Hamish Cameron

Dr Hamish Cameron was formerly CEO at Cambridge Antibody Technology.

Stephen Donnelly, CFO

Stephen has over ten year’s experience working with healthcare companies. He holds professional accounting and company secretarial qualifications and previous positions in the industry include Chief Accountant/Company Secretary for Anagen PLC, a diagnostic company quoted on the LSE, and CFO/Company Secretary of Alfa Biotech (UK) Limited, a UK subsidiary of an Italian pharmaceutical company. Stephen has also had a senior management role with other venture capital healthcare companies including Novarticulate Holdings Ltd. and Rodaris Pharmaceuticals Ltd. In addition to these roles in the healthcare industry he also held the position of Director of Finance and Administration for the London Office of The Nasdaq Stock Market Inc.

Martin Edwards

Robert Haigh, CSO

Dr Robert Haigh holds a Masters in Biochemistry and a PhD in Medicine both from Manchester University. Following a successful Research Fellowship at Oxford University, he began his pharmaceutical career in drug discovery and has held positions of increasing responsibility in R&D during a 17 year career with Boehringer Ingelheim and Ferring Pharmaceuticals.

As Managing Director and VP Research, Robert transformed Ferring Research Ltd from an academic research institute into a productive pharmaceutical research centre and in 2008 he led the spin-out of the site.

During his career, he has lived and worked in the UK and Germany and has held board level positions in Europe and the USA.

Robert is a Founder of Vantia Therapeutics.

Hilary McElwaine-Johnn, CMO

David McGibney

Dr David McGibney was formerly Head of R&D at Pfizer.

Alex Pasteur

Dr. Alex Pasteur joined MVM in September 2005. From 2001 to 2005 he was a member of the life sciences investment team at the Cambridge Gateway Fund. Prior to that Dr. Pasteur's experience includes consulting with OC&C Strategy Consultants Ltd in London, a Ph.D. in Chemistry (Cambridge) in 1996 and a degree in Natural Sciences(Cambridge).